Synaffix

Biotechnology Research • Amsterdam, North Holland, Netherlands • 51-100 Employees

Company overview

Headquarters	Amsterdam, North Holland, Netherlands
Phone number	+31880224505
Website	synaffix.com
NAICS	541714
SIC	873
Keywords	Antibody-Drug Conjugates (Adcs), Bispecific Antibodies, Cell Engagers, Targeted Gene Therapy
Employees	51-100
Socials

Key Contacts at Synaffix

Sven Zimmer

Associate Director Business Development

Floris Van Delft

Founder And Cso Of Synaffix Bv

Peter Van De Sande

Ceo

Marcel Scheepstra

Director Organic Chemistry

Synaffix Email Formats

Synaffix uses 1 email format. The most common is {first initial}.{last name} (e.g., j.doe@synaffix.com), used 100% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@synaffix.com	100%

About Synaffix

Synaffix BV is a biotech company that has established a proprietary, clinical-stage antibody-drug conjugate (ADC) technology platform that delivers best-in-class ADCs (safety and efficacy). Our platform is commercially validated by well over $7.6 billion in technology out-licensing deals with partners including ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio and Kyowa Kirin. These partnerships have rapidly translated Synaffix technology into >20 ADCs currently in development by our partners, where 5 of these have already initiated Phase 1 clinical trials. Through the platform, we can rapidly generate best-in-class ADCs for our partners from any antibody and our patent portfolio protects our proprietary processes and any resulting Products through at least 2039. Additionally, Synaffix technology is being deployed to address unmet medical need in several multi-billion-dollar, high growth market segments such as immune cell engagers and targeted gene therapy. Synaffix BV was acquired by Lonza in May 2023.

Synaffix revenue & valuation

Annual revenue	$6,000,000
Revenue per employee	$89,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$19,200,000
Total funding	No funding